Project Grant R15CA267840
Award Date
9/5/22
Completion Date
8/31/25
Dollars Obligated
$808K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Oregon, USA
Similar Awards
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) will provide $606,869 to Case Western Reserve University from July 2024 through June 2029 to study the mechanisms of androgen receptor inverse agonists in treating advanced prostate cancer. The research aims to map the epigenetic mechanisms driving treatment-resistant metastatic castration-resistant prostate cancer, and to develop novel small molecule therapies that can functionally...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, supports research to understand how the androgen receptor (AR) transcription factor regulates normal and oncogenic gene expression programs in prostate cancer. The $564,543 award to Weill Medical College of Cornell University, effective March 1, 2025, will fund a 5-year research project to determine the factors that allow the reactivation of the AR's...
This federal Project Grant award, with ID R01CA285526, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The $549,357 award supports research by The Washington University in St. Louis to investigate the regulation of the androgen receptor (AR) by a long non-coding RNA called NXTAR in prostate cancer. The key objectives are to determine the mechanism of NXTAR suppression in castration-resistant prostate cancers, develop PSMA-targeted...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $624,001 to New York University School of Medicine to develop a new class of compounds called multivalent peptoid conjugates (MPCs) that can antagonize the androgen receptor (AR) in prostate cancer cells. The project aims to demonstrate that these novel MPC compounds can stop the growth of prostate cancer cells that have become resistant to standard anti-androgen treatments....
This federal Project Grant award, ID R01CA301628, was provided by the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to Tulane University. The $632,906 award, effective from April 1, 2025 to March 31, 2030, supports research to investigate the role of androgen receptor (AR) RNA-binding activity in prostate cancer progression and therapeutic resistance. The study aims to elucidate how AR binding to splicing factor transcripts promotes efficient splicing and expression of genes...
This federal Project Grant award in the amount of $535,334.00 was provided by the National Cancer Institute (NCI) under the Cancer Biology Research (CFDA 93.396) program. The grant supports a research project led by Albert Einstein College of Medicine to investigate the non-autonomous role of androgen signaling in prostate cancer tumorigenesis. The key focus of the project is to study how androgen receptor (AR) signaling in prostatic stromal cells, specifically those expressing the GLI1...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $472,458 to The University of Texas Southwestern Medical Center to conduct research on overcoming mechanisms of PTPN1 driving therapy- and castration-resistant prostate cancer. The key objectives are to examine the regulation of the PTPN1 gene by anti-androgen therapies, uncover the PTPN1-related regulatory network, and identify downstream effectors of PTPN1 that promote the...
The National Cancer Institute (NCI) awarded a $1,304,828 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Washington University in St. Louis to conduct a Phase 1 clinical trial assessing the safety, tolerability, pharmacokinetics, and anti-tumor activity of the novel ACK1 inhibitor (R)-9B in patients with castration-resistant prostate cancer (CRPC). The grant will support specific aims to: 1) evaluate the safety and tolerability of (R)-9B, and 2) assess peripheral blood and tumor...
This federal Project Grant award of $571,271 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will fund research to develop a targeted drug conjugate for the treatment of metastatic castration-resistant prostate cancer (MCRPC). The research team at the University of Texas Health Science Center at Houston will synthesize a prostate-specific membrane antigen (PSMA)-targeted drug conjugate containing the microtubule inhibitor cryptophycin, visualize and quantify the in...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,082,472.00 to Emory University to determine the molecular mechanisms underlying the progression of prostate adenocarcinoma (ADPC) to the lethal neuroendocrine prostate cancer (NEPC) subtype. The key objectives are to: Investigate the role of the transcription factors FOXA2 and NKX2-1 in driving the luminal-to-neuroendocrine transdifferentiation process, including evaluating...